Sapablursen

Phase 3RNA therapy

Ionis Pharmaceuticals

Sapablursen is one of 37 small molecule programs targeting Polycythemia Vera. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

Polycythemia VeraPhase 3

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Polycythemia Vera

#DrugCompanyPhaseTrials

Droxia

TTheravia

Approved

5 2

BESREMI

PPharmaEssentia

Approved

3 3

Jakafi

Incyte

Phase 3

10 4

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—5

Ojjaara

GGlaxo Dba Glaxosmithkline

Trisenox

PEG-Intron

Duvyzat

3 9

Best Available Therapy

Novartis

Phase 3

2 10

Bayer Aspirin

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 3Recruiting

Polycythemia Vera

NCT07429266

Clinical

Trials by Indication[1]

Polycythemia Vera2 trials

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 2·NCT05143957·50 enrolled

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 3·NCT07429266·250 enrolled

Efficacy1 trial

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Terminated· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 2·NCT04059406·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Sapablursen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sapablursen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sapablursen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ionis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: Ionis Pharmaceuticals

Sapablursen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Polycythemia Vera2 trials

Efficacy1 trial

References

Drug Info

Quick Facts

Related News